Company profile
biopharma and diagnostics · Basel, Switzerland · roche.com
Roche is a global healthcare company focused on pharmaceuticals and diagnostics, with a strategy centered on preventing, stopping, curing disease. Current public disclosures show continued emphasis on oncology, neuroscience, cardiovascular and metabolic disease, alongside digital pathology, AI, external partnerships.
The company frames its model around combining medicines and diagnostics to improve outcomes and reduce costs.
Strategy page says Roche aims to prevent, stop, cure diseases and stresses the seamless integration of pharmaceuticals and diagnostics.
Roche publicly positions collaboration as a core way to expand innovation and integrated solutions.
Strategy page says Roche works with third parties, collaborates across the healthcare ecosystem, has alliances with over 250 external partners.
Recent disclosures show Roche increasing compute capacity and embedding AI across discovery, development, manufacturing, commercialisation.
Roche announced an AI factory with more than 3,500 GPUs and said it supports an AI accelerated healthcare organisation.
Roche is building digital pathology offerings that allow third party tools to connect to its platform.
The Digital Pathology Open Environment provides access to third party image analysis tools alongside Roche AI algorithms and lists multiple collaborators.
Roche appears to use a hybrid cloud and on premises technology posture, with cloud enabled workflows in procurement, diagnostics, AI infrastructure.
Public disclosures point to hybrid cloud compute, cloud native supplier tools, open digital pathology integrations, heavy AI use in research and diagnostics.
This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.
Generate a full briefYour first brief is free, no card required.
Evidence confidence 89/100. Generated 2026-07-03 from public sources.